Published in Intern Med on April 01, 2010
Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter (2011) 2.00
The Role of CD44 in the Pathogenesis, Diagnosis, and Therapy of Gastric Cancer. Gut Liver (2011) 1.11
D1 versus D2 lymphadenectomy for gastric cancer. J Surg Oncol (2012) 1.11
Strategy for eliminating gastric cancer in Japan. Helicobacter (2010) 1.08
Gastric cancer: prevention, screening and early diagnosis. World J Gastroenterol (2014) 1.03
Applicability of a rapid stool antigen test, using monoclonal antibody to catalase, for the management of Helicobacter pylori infection. J Gastroenterol (2011) 0.87
Observation of gastric mucosa in Bangladesh, the country with the lowest incidence of gastric cancer, and Japan, the country with the highest incidence. Helicobacter (2012) 0.87
Serum Helicobacter pylori NapA antibody as a potential biomarker for gastric cancer. Sci Rep (2014) 0.85
Current evidence of effects of Helicobacter pylori eradication on prevention of gastric cancer. Korean J Intern Med (2013) 0.83
Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategies. World J Hepatol (2012) 0.81
Case-control study of association of eosinophilic gastrointestinal disorders with Helicobacter pylori infection in Japan. J Clin Biochem Nutr (2013) 0.79
Does herbal medicine reduce the risk of hepatocellular carcinoma? World J Gastroenterol (2015) 0.78
Gastric cancer development after the successful eradication of Helicobacter pylori. World J Gastrointest Oncol (2016) 0.75
Risk Factors for Metachronous Recurrence after Endoscopic Submucosal Dissection of Early Gastric Cancer. J Korean Med Sci (2017) 0.75
Anti-inflammatory drugs reduce the risk of hepatocellular carcinoma development. ISRN Oncol (2011) 0.75
Pathogenesis and risk factors for gastric cancer after Helicobacter pylori eradication. World J Gastrointest Oncol (2016) 0.75
Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut (2012) 12.62
Traces of human migrations in Helicobacter pylori populations. Science (2003) 11.92
Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis (2002) 5.09
Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med (2011) 3.78
Norwalk virus shedding after experimental human infection. Emerg Infect Dis (2008) 3.70
Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol (2005) 3.34
Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology (2002) 3.27
The peopling of the Pacific from a bacterial perspective. Science (2009) 3.14
Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score. J Clin Gastroenterol (2012) 2.99
Gastroesophageal reflux among different racial groups in the United States. Gastroenterology (2004) 2.87
Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood. Lancet (2002) 2.71
Helicobacter pylori in North and South America before Columbus. FEBS Lett (2002) 2.57
Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter (2010) 2.50
Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis (2013) 2.50
A report card to grade Helicobacter pylori therapy. Helicobacter (2007) 2.41
Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology (2002) 2.32
Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig Endosc (2013) 2.30
Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis (2010) 2.21
Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol (2009) 2.15
Comparing the Blatchford and pre-endoscopic Rockall score in predicting the need for endoscopic therapy in patients with upper GI hemorrhage. Gastrointest Endosc (2010) 2.04
Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology (2005) 2.03
Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter (2009) 2.02
Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol (2011) 1.98
Relationship between histopathologic gastritis and mucosal microvascularity: observations with magnifying endoscopy. Gastrointest Endosc (2003) 1.96
Gastritis staging in clinical practice: the OLGA staging system. Gut (2006) 1.90
Risk factors for immediate and delayed bleeding associated with endoscopic submucosal dissection of gastric neoplastic lesions. Scand J Gastroenterol (2009) 1.75
NSAIDs, Helicobacter pylori, and Pandora's Box. N Engl J Med (2002) 1.75
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter (2011) 1.73
Discrimination between cases of duodenal ulcer and gastritis on the basis of putative virulence factors of Helicobacter pylori. J Clin Microbiol (2002) 1.72
Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer (2002) 1.69
Biliary stenting in the management of large or multiple common bile duct stones. Gastrointest Endosc (2010) 1.68
Design and planned analyses of an ongoing randomized trial assessing the preventive effect of Helicobacter pylori eradication on occurrence of new gastric carcinomas after endoscopic resection. Helicobacter (2006) 1.67
Characteristics of magnified endoscopic images of gastric extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue, including changes after treatment. Gastrointest Endosc (2008) 1.67
Long-term outcome after endoscopic mucosal resection in patients with esophageal squamous cell carcinoma invading the muscularis mucosae or deeper. Gastrointest Endosc (2002) 1.65
Management of gastric polyps: a pathology-based guide for gastroenterologists. Nat Rev Gastroenterol Hepatol (2009) 1.62
Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern Med (2008) 1.62
Role of interferon-stimulated responsive element-like element in interleukin-8 promoter in Helicobacter pylori infection. Gastroenterology (2004) 1.59
Helicobacter pylori infection in mice: Role of outer membrane proteins in colonization and inflammation. Gastroenterology (2002) 1.58
Iron deficiency and Helicobacter pylori infection in the United States. Am J Epidemiol (2005) 1.57
Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. J Gastroenterol (2003) 1.57
Endoscopic demonstration of transient small bowel intussusception in a patient with adult celiac disease. Gastrointest Endosc (2003) 1.55
Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology (2002) 1.54
Helicobacter pylori-negative gastritis: prevalence and risk factors. Am J Gastroenterol (2012) 1.51
Horizontal versus familial transmission of Helicobacter pylori. PLoS Pathog (2008) 1.48
Helicobacter pylori eradication and change in markers of iron stores among non-iron-deficient children in El Paso, Texas: an etiologic intervention study. J Pediatr Gastroenterol Nutr (2011) 1.47
Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol (2007) 1.45
Helicobacter pylori virulence factors: facts and fantasies. Curr Opin Gastroenterol (2005) 1.44
Etest for metronidazole susceptibility in H. pylori: use of the wrong standard may have led to the wrong conclusion. Am J Gastroenterol (2004) 1.43
Effect of the carbonic anhydrase inhibitor, acetazolamide, on Helicobacter pylori infection in vivo: a pilot study. Helicobacter (2005) 1.42
Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett's esophagus in white men. Clin Gastroenterol Hepatol (2012) 1.41
Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection. J Immunol (2006) 1.41
Double-blind randomized trial of quadruple sequential Helicobacter pylori eradication therapy in asymptomatic infected children in El Paso, Texas. J Pediatr Gastroenterol Nutr (2011) 1.40
Helicobacter pylori infection--a boon or a bane: lessons from studies in a low-prevalence population. Helicobacter (2013) 1.38
Regulation of interleukin-6 promoter activation in gastric epithelial cells infected with Helicobacter pylori. Mol Biol Cell (2005) 1.37
Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med (2002) 1.35
Molecular epidemiology and outcome of Helicobacter pylori infection in Thailand: a cultural cross roads. Helicobacter (2004) 1.35
Clinical presentation in relation to diversity within the Helicobacter pylori cag pathogenicity island. Am J Gastroenterol (2002) 1.34
Endoscopic diagnosis of early squamous neoplasia of the esophagus with iodine staining: high-grade intra-epithelial neoplasia turns pink within a few minutes. J Gastroenterol Hepatol (2007) 1.33
Diagnosis and management of iron deficiency anemia in the 21st century. Therap Adv Gastroenterol (2011) 1.30
Helicobacter pylori infection in Kazakhstan: effect of water source and household hygiene. Am J Trop Med Hyg (2002) 1.29
Endoscopic submucosal dissection for treatment of early stage hypopharyngeal carcinoma. Gastrointest Endosc (2006) 1.28
Eradication of gastric cancer is now both possible and practical. Semin Cancer Biol (2013) 1.28
Correlation between Helicobacter pylori OipA protein expression and oipA gene switch status. J Clin Microbiol (2004) 1.27
Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. Gastroenterol Clin North Am (2010) 1.26
Helicobacter pylori and hetertopic gastric mucosa in the upper esophagus (the inlet patch). Am J Gastroenterol (2003) 1.25
Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers. Scand J Gastroenterol (2007) 1.22
Helicobacter pylori virulence and cancer pathogenesis. Future Oncol (2014) 1.21
Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter (2011) 1.21
Serological responses to experimental Norwalk virus infection measured using a quantitative duplex time-resolved fluorescence immunoassay. Clin Vaccine Immunol (2011) 1.20
Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study. J Gastroenterol Hepatol (2012) 1.20
Helicobacter pylori impairs DNA mismatch repair in gastric epithelial cells. Gastroenterology (2002) 1.19
Helicobacter pylori activate epidermal growth factor receptor- and phosphatidylinositol 3-OH kinase-dependent Akt and glycogen synthase kinase 3beta phosphorylation. Cell Microbiol (2008) 1.19
vacA i-region subtyping. Gastroenterology (2008) 1.18
The ability of a novel blue laser imaging system for the diagnosis of invasion depth of colorectal neoplasms. J Gastroenterol (2013) 1.18
Diet, lifestyle and gender in gastro-esophageal reflux disease. Dig Dis Sci (2007) 1.16
Management of gastric polyps: an endoscopy-based approach. Clin Gastroenterol Hepatol (2013) 1.15
Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. Gut (2013) 1.14
Role of deletion located between the intermediate and middle regions of the Helicobacter pylori vacA gene in cases of gastroduodenal diseases. J Clin Microbiol (2009) 1.13
Comparison of genotyping Helicobacter pylori directly from biopsy specimens and genotyping from bacterial cultures. J Clin Microbiol (2003) 1.13
Clinicopathological analysis of early-stage gastric cancers detected after successful eradication of Helicobacter pylori. Helicobacter (2011) 1.12
Spontaneous resolution of cap polyposis: case report. Gastrointest Endosc (2003) 1.12
Regulation of RANTES promoter activation in gastric epithelial cells infected with Helicobacter pylori. Infect Immun (2005) 1.12
Cross-reactivity of anti-CagA antibodies with vascular wall antigens: possible pathogenic link between Helicobacter pylori infection and atherosclerosis. Circulation (2002) 1.11
The Role of CD44 in the Pathogenesis, Diagnosis, and Therapy of Gastric Cancer. Gut Liver (2011) 1.11
Molecular markers in Helicobacter pylori-associated gastric carcinogenesis. Clin Lab Med (2005) 1.11
Real-time monitoring of a digestive tract marker to reduce adverse effects of moving organs at risk (OAR) in radiotherapy for thoracic and abdominal tumors. Int J Radiat Oncol Biol Phys (2005) 1.10
Preliminary trial of rebamipide for prevention of low-dose aspirin-induced gastric injury in healthy subjects: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Biochem Nutr (2009) 1.10
Which Therapy for Helicobacter pylori Infection? Gastroenterology (2012) 1.10
Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus. Clin Vaccine Immunol (2011) 1.10
Genetic analysis of Helicobacter pylori strain populations colonizing the stomach at different times postinfection. J Bacteriol (2007) 1.09
Helicobacter pylori research: historical insights and future directions. Nat Rev Gastroenterol Hepatol (2013) 1.09
Gastric mucosal interleukin-17 and -18 mRNA expression in Helicobacter pylori-induced Mongolian gerbils. Cancer Sci (2009) 1.09
What is an adequate management strategy for pharyngeal low-grade dysplasia? Gastrointest Endosc (2013) 1.08
Strategy for eliminating gastric cancer in Japan. Helicobacter (2010) 1.08
Evidence-based clinical practice guidelines for functional dyspepsia. J Gastroenterol (2015) 1.08
Helicobacter pylori BabA expression, gastric mucosal injury, and clinical outcome. Clin Gastroenterol Hepatol (2006) 1.08
Randomized, double-blind, pilot study of geranylgeranylacetone versus placebo in patients taking low-dose enteric-coated aspirin. Low-dose aspirin-induced small bowel damage. Scand J Gastroenterol (2010) 1.07